Pharmaceuticals news FT.com

Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech

US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda

Jun 2, 2025 - 12:20
 0
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Read More

Tags:

Previous Article

Bristol Myers allies with BioNTech on bispecific cancer drug

Next Article

STAT+: Kymera reports early-stage success for drug meant to rival Sanofi and Reg...

Related Posts

GSK buys Boston Pharmaceutical’s new liver disease drug for up to $2bn

GSK buys Boston Pharmaceutical’s new liver disease drug...

May 14, 2025  0

23andMe sale grafts a happy ending on to a glum tale

23andMe sale grafts a happy ending on to a glum tale

May 20, 2025  0

Scientists give pioneering gene therapy to infant patient

Scientists give pioneering gene therapy to infant patient

May 15, 2025  0